Current - Members - Nanomedicine Research Group

Login Form

Last Updated: July 2019

Principal Investigator

Pieter Cullis, PhD, FRSC

Read More


Research Associates

Genc Basha, MD, PhD

The focus of my research includes the mechanism of uptake and intracellular trafficking of liposomal nanoparticles and gene targeting in antigen presenting cells (DCs) and tumor cells.

Igor Zhigaltsev, PhD

My areas of interest include the design, formulation, physicochemical characterization and in vitro and in vivo evaluation of liposome-based drug forms. Specific methods and techniques used in my research include: preformed vesicle approach, remote loading techniques, freeze-fracture and transmission electron microscopy, evaluation of in vivo pharmacokinetics of liposomal drugs.


Post-doctoral Fellows

Dominik Witzigmann, PhD

My research is focused on targeted DNA therapeutics for the treatment of orphan monogenetic liver disorders and the development of lipid-based nanomedicines for the delivery of biomacromolecules. A key step in this development process is the investigation of nano-bio interactions at an organ and cellular level. Financial support for this research is provided by the Swiss National Science Foundation.
For more information:


Graduate Students

Nisha Chander, B.Tech, M.Sc

Pending details.

Mina Ordobadi, B.Sc

My project focuses on developing lipid nanoparticles for targeted delivery to bones. These nanoparticles can be loaded with a variety of small molecules and drugs using different encapsulation techniques and are potential therapeutics for treatment of bone diseases such as osteoporosis.



Cayetana Schluter, MSc
Laboratory Manager

Pending details.


Visiting Scientists and Associated Members

Theresa M. Allen, PhD, FRSC
Adjunct Professor, NanoMedicines Research Group, Dept. of Biochemistry & Molecular Biology, UBC, Vancouver
Professor Emeritus, Pharmacology & Oncology, University of Alberta, Edmonton
Co-founder and Strategic Advisor, Centre for Drug Research and Development (CDRD), Vancouver


Robert (Rob) Fraser, PhD
Co-Founder & Operations Officer BCPMI (BC Personalized Medicine Initiative)
Rob has been involved in pharmaceutical research and development community for over 13 years; group leader in Target Identification for Sanofi; Senior Director of Biology for Xenon Pharmaceuticals, Senior Director of Pharmacology and Site Director at Neuromed (now Zalicus) Director Project Evaluation, CDRD. With a strong background and success rate in the development of targeted therapeutics, and recognizing the need to better target the therapy to the individual to improve safety and efficacy, Dr. Fraser joined Dr. Cullis at the start of 2011 to establish the Personalized Medicine Initiative for BC, which is a major opportunity for multiple institutions and stakeholders within BC to work together to lead a transformative process that will improve healthcare in BC.